The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | The management of patients with myeloma who are anti-CD38 refractory
The number of anti-CD38 refractory patients with multiple myeloma (MM) is increasing, creating a major clinical challenge. Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the approved therapeutic approaches that can be utilized to manage these patients and highlights some alternative treatment strategies that are being explored. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
